Product review demonstrates high efficacy and real-world effectiveness of nirsevimab against RSV hospitalization in infants, highlighting a scalable passive immunization strategy.
Infant RSV prevention is undergoing a public-health paradigm shift toward scalable, broad-eligibility passive immunization. This review examines nirsevimab (Beyfortus®), a long-acting recombinant IgG1κ monoclonal antibody targeting the conserved site Ø of prefusion RSV F protein. Its extended half-life enables season-long protection with a single dose, overcoming key limitations of palivizumab. A validated manufacturing platform and stringent release specifications ensure consistent quality and potency. Pivotal trials demonstrated high efficacy against RSV-associated lower respiratory tract infection hospitalization (RSVH), while the pragmatic HARMONIE trial confirmed an 83.2% reduction in RSVH under routine conditions. Postlicensure studies across multiple countries report 70–90% effectiveness against RSVH and substantial reductions in intensive care admissions. Comparative 2024–2025 data further suggest greater protection than maternal RSVpreF vaccination. Nirsevimab represents a scalable public-health intervention that can be used alone or complement maternal RSV vaccination, warranting continued surveillance of effectiveness, safety, and viral escape.
No takes yet. Share an insight, caveat, or question.
Razzini et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: